Elevation Oncology
ELEV
ELEV was delisted on the 22nd of July, 2025.
22 hedge funds and large institutions have $123M invested in Elevation Oncology in 2021 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 20 closing their positions.
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
2.58% less ownership
Funds ownership: 70.96% → 68.37% (-2.6%)
39% less funds holding
Funds holding: 36 → 22 (-14)
43% less capital invested
Capital invested by funds: $217M → $123M (-$94M)
70% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.44M |
| 2 |
Janus Henderson Group
London,
|
+$2.04M |
| 3 |
BlackRock
New York
|
+$258K |
| 4 |
State Street
Boston,
Massachusetts
|
+$200K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$131K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$1.9M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.7M |
| 3 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
-$1.7M |
| 4 |
Millennium Management
New York
|
-$1.67M |
| 5 |
GTC
Ghost Tree Capital
New York
|
-$1.36M |
ELEV Hedge Fund Activity: Q3 2021 in Review
22 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Elevation Oncology (ELEV) for Q3 2021, worth a combined $123M — down 43% from $217M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of ELEV and 6 opened new positions — a net loss of 14 holders — while 4 trimmed existing stakes and 5 added.
The largest buyer was Vanguard Group, adding an estimated $6.44M. The largest seller was Monashee Investment Management, exiting entirely with an estimated $1.9M sold.
- 22 institutional investors held Elevation Oncology (ELEV) as of Q3 2021, down from 36 in Q2 2021.
- Funds reported $123M of Elevation Oncology stock for Q3 2021, down 43% quarter-over-quarter.
- 6 funds opened new Elevation Oncology positions in Q3 2021 and 20 closed out, a net change of -14 holders.
- The largest Elevation Oncology buyer in Q3 2021 was Vanguard Group, an estimated $6.44M added.
- The largest Elevation Oncology seller in Q3 2021 was Monashee Investment Management, an estimated $1.9M sold.
Based on aggregated 13F filings for Q3 2021.